Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CADL
stocks logo

CADL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.254
-36.46%
--
--
-0.170
-230.77%
--
--
-0.195
+116.67%
Estimates Revision
The market is revising No Change the revenue expectations for Candel Therapeutics, Inc. (CADL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.20%.
EPS Estimates for FY2025
Revise Upward
up Image
+17.93%
In Past 3 Month
Stock Price
Go Up
up Image
+5.20%
In Past 3 Month
Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is 18.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is 18.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.260
sliders
Low
7.00
Averages
18.33
High
25.00
Current: 5.260
sliders
Low
7.00
Averages
18.33
High
25.00
Citi
Yigal Nochomovitz
Buy
downgrade
$25 -> $24
2025-11-14
Reason
Citi
Yigal Nochomovitz
Price Target
$25 -> $24
2025-11-14
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Candel Therapeutics to $24 from $25 and keeps a Buy rating on the shares.
Stephens
Stephens
Overweight
initiated
$15
2025-10-28
Reason
Stephens
Stephens
Price Target
$15
2025-10-28
initiated
Overweight
Reason
As previously reported, Stephens initiated coverage of Candel Therapeutics with an Overweight rating and $15 price target. Though financing and market penetration remain "open questions," the company's pipeline represents "a differentiated and potentially transformative entry" within next-generation therapeutic modalities with lead asset CAN-2409 functioning as an augmentative therapy designed to complement, rather than replace, existing standards of care, which the firm sees limiting competitive pressures and allowing for broad application across multiple indications.
Stephens
Stephens
initiated
$15
2025-10-27
Reason
Stephens
Stephens
Price Target
$15
2025-10-27
initiated
Reason
Stephens initiated coverage of Candel Therapeutics with an Overweight rating and $15 price target.
LifeSci Capital
initiated
$16
2025-10-21
Reason
LifeSci Capital
Price Target
$16
2025-10-21
initiated
Reason
LifeSci Capital initiated coverage of Candel Therapeutics with an Outperform rating and $16 price target.
BofA
Buy -> Neutral
downgrade
$7
2025-09-03
Reason
BofA
Price Target
$7
2025-09-03
downgrade
Buy -> Neutral
Reason
BofA downgraded Candel Therapeutics to Neutral from Buy with a $7 price target.
BofA
Buy -> Neutral
downgrade
$13 -> $7
2025-09-03
Reason
BofA
Price Target
$13 -> $7
2025-09-03
downgrade
Buy -> Neutral
Reason
As previously reported, BofA downgraded Candel Therapeutics to Neutral from Buy with a price target of $7, down from $13. The firm sees catalyst flow picking up for its small-to-mid sized biotech coverage heading into early 2026, but would deprioritize stocks without near-term catalysts given the environment it would argue "has been more rewarding for positive clinical data than in recent years." For Candel in particular, the firm sees "a relative catalyst desert" until a BLA filing in Q4 of 2026 and views pipeline development as likely conditional on additional financing, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Candel Therapeutics Inc (CADL.O) is -5.90, compared to its 5-year average forward P/E of -5.01. For a more detailed relative valuation and DCF analysis to assess Candel Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.01
Current PE
-5.90
Overvalued PE
-1.65
Undervalued PE
-8.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.44
Undervalued EV/EBITDA
-5.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
645.95
Current PS
0.00
Overvalued PS
1617.57
Undervalued PS
-325.66
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CADL News & Events

Events Timeline

(ET)
2025-11-13
08:27:54
Candel Therapeutics announces Q3 earnings per share of 21 cents, compared to a loss of 33 cents in the previous year.
select
2025-11-04 (ET)
2025-11-04
09:07:32
Candel Therapeutics to Present Three Talks at SITC
select
2025-10-16 (ET)
2025-10-16
08:19:29
Candel Therapeutics Names Pulendran to Its RAB
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-18Newsfilter
Candel Therapeutics to Hold Online R&D Event on December 5, 2025

  • Candel Therapeutics R&D Event: Candel Therapeutics will host a virtual Research and Development Day on December 5, 2025, featuring presentations and discussions on their viral immunotherapy approach and oncology pipeline, including insights from leading experts in the field.

  • Focus on CAN-2409 and CAN-3110: The event will highlight Candel's lead product candidates, CAN-2409 and CAN-3110, which are designed to treat various cancers through innovative immunotherapy methods, with promising results from ongoing clinical trials.

  • Regulatory Designations: CAN-2409 has received multiple regulatory designations from the FDA, including Fast Track and Orphan Drug Designations, indicating its potential in treating difficult-to-treat solid tumors like localized prostate cancer and non-small cell lung cancer.

  • Forward-Looking Statements: The company cautions that the information shared includes forward-looking statements that are subject to risks and uncertainties, which may affect the actual outcomes of their development programs and regulatory approvals.

[object Object]
Preview
4.0
11-15NASDAQ.COM
Citigroup Upholds Buy Rating for Candel Therapeutics (CADL)

  • Analyst Recommendation: Citigroup has maintained a Buy recommendation for Candel Therapeutics, with a projected one-year price target of $19.38/share, indicating a potential upside of 316.33% from its current price of $4.66/share.

  • Fund Sentiment: There are 179 funds reporting positions in Candel Therapeutics, with a slight increase in ownership. The average portfolio weight for these funds is 0.07%, and the total shares owned by institutions decreased by 0.41% over the last three months.

  • Shareholder Activity: Notable shareholders include FBIOX, Acorn Capital Advisors, and IWM, with varying changes in their holdings. Acorn Capital Advisors increased its stake by 16.60%, while Portolan Capital Management decreased its holdings by 17.16%.

  • Market Outlook: The put/call ratio for Candel Therapeutics is 0.33, suggesting a bullish outlook among investors, while the projected annual revenue is expected to rise significantly by 79,854.84%.

[object Object]
Preview
9.0
11-14SeekingAlpha
Candel Halts Development of CAN-2409 for Prostate Cancer

  • Development Pause: Candel Therapeutics is pausing the development of CAN-2409 for borderline resectable pancreatic adenocarcinoma to focus on localized, intermediate/high risk pancreatic cancer and non-small cell lung cancer (NSCLC).

  • Clinical Trials Update: The company is preparing for a Biologics License Application (BLA) submission for CAN-2409 in localized pancreatic cancer and plans to initiate a phase 3 study in NSCLC by Q2 2026.

  • Financial Performance: Candel's Q3 financial results fell short of expectations, indicating challenges in their financial performance.

  • Market Reactions: The stock prices of Candel and other biopharma companies like Erasca and Xencor have declined following a downgrade by BofA due to a perceived lack of near-term catalysts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Candel Therapeutics Inc (CADL) stock price today?

The current price of CADL is 5.26 USD — it has increased 4.78 % in the last trading day.

arrow icon

What is Candel Therapeutics Inc (CADL)'s business?

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

arrow icon

What is the price predicton of CADL Stock?

Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is 18.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Candel Therapeutics Inc (CADL)'s revenue for the last quarter?

Candel Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Candel Therapeutics Inc (CADL)'s earnings per share (EPS) for the last quarter?

Candel Therapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -36.36 % YoY.

arrow icon

What changes have occurred in the market's expectations for Candel Therapeutics Inc (CADL)'s fundamentals?

The market is revising No Change the revenue expectations for Candel Therapeutics, Inc. (CADL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.20%.
arrow icon

How many employees does Candel Therapeutics Inc (CADL). have?

Candel Therapeutics Inc (CADL) has 38 emplpoyees as of December 05 2025.

arrow icon

What is Candel Therapeutics Inc (CADL) market cap?

Today CADL has the market capitalization of 288.22M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free